CEO & Co-Founder

Shorla Oncology Announces FDA Orphan Drug Designation for SH-110 to Treat Rare Brain Cancer Using Oral Liquid

Stable formulations comprising thiotepa

Shorla wins FDA nod for ready-to-dilute Tepylute

Clonmel-based Shorla Oncology to increase revenues significantly

Oncology Key Account Manager

Shorla Oncology is dedicated to developing affordable and accessible oncology medicines for underserved populations. They are seeking two Oncology Key Account Managers to drive growth and market penetration across various healthcare facilities while collaborating with cross-functional teams to enhance patient access to their oncology portfolio.

Sign up with Google

Sign in with Google